^
    Back
    Association details:
    Biomarker:ER positive
    Cancer:Estrogen Receptor Positive Breast Cancer
    Drug:Jingzhuda (entinostat) (HDAC inhibitor, HDAC1 inhibitor, HDAC2 inhibitor, HDAC3 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer

    Excerpt:
    ...- Histologically or cytologically confirmed estrogen receptor positive (ER+) breast cancer...
    Trial ID:
    ENCORE301
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Nat Commun
    Title:

    Transcriptional repression of estrogen receptor alpha by YAP reveals the Hippo pathway as therapeutic target for ER + breast cancer

    Published date:
    02/25/2022
    Excerpt:
    We developed a potent LATS inhibitor VT02956. Targeting the Hippo pathway by VT02956 represses ESR1 expression and inhibits the growth of ER+ breast cancer cells as well as patient-derived tumour organoids. Moreover, histone deacetylase inhibitors, such as Entinostat, induce VGLL3 expression to inhibit ER+ breast cancer cells.
    DOI:
    10.1038/s41467-022-28691-0